Maze Therapeutics, Inc. (MAZE) financial statements and ratios from SEC XBRL: revenue $167.50M (TTM), net margin 31.2%, revenue growth -100.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $167.50M |
| Net Margin | 31.2% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -178.6% |
| FCF Growth (YoY) | -121.0% |
| Price / Book | 3.55 |
| Price / Sales | 26.80 |
| FCF Yield | -13.5% |
| Altman Z-Score | 18.82 (safe) |
| Sector P/E (Healthcare) | 21.6 |
MAZE overview · MAZE earnings · MAZE KPIs · MAZE investor relations · MAZE ownership · MAZE peers · MAZE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.